IP Library Granted Patent US 11,066,451
Granted Patent B2
US 11,066,451 · App. 15/765,427 · Granted Jul 20, 2021

Methods for purifying clostridial neurotoxin

Inventors: Gavin Stephen Hackett (Milton Keynes, GB); Shilpa Palan (Oxfordshire, GB); Dina Brady Anderson (Abingdon, GB)
Assignee: IPSEN BIOPHARM LIMITED
C07K14/33C12N9/52C12Y304/24068C12Y304/24069
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,066,451
App. No.
15/765,427
Granted
Jul 20, 2021
Kind
B2
Abstract

A method for purifying a clostridial neurotoxin comprising contacting a cation exchange resin with a composition comprising a clostridial neurotoxin, wherein the contacting step is performed at at least pH 7.3, wherein the step of contacting a cation exchange resin with a composition comprising said clostridial neurotoxin occurs prior to conversion of the clostridial neurotoxin from a single chain form into a dichain form. Also provided are uses of a buffer having a pH value that is −1 pH unit or higher than the calculated pi of a clostridial neurotoxin, purification intermediates and clostridial neurotoxins obtainable by the invention, wherein the clostridial neurotoxin is in a single chain form.

Claims (20)

1. A method of producing the active di-chain form of a clostridial neurotoxin, the method comprising:

(a) contacting a cation exchange resin with a composition comprising a single-chain clostridial neurotoxin, wherein the contacting step is performed at a pH of from 7.3 to 9.5;

(b) separating the clostridial neurotoxin from the cation exchange resin and

(c) contacting the separated clostridial neurotoxin with a protease that cleaves the polypeptide sequence of the clostridial neurotoxin under conditions suitable for the cleavage, thereby activating it to produce the active di-chain form of the clostridial neurotoxin,

wherein the step (a) occurs before the step (b).

2. The method of claim 1 , wherein the separated clostridial neurotoxin is in a substantially pure state.

3. The method of claim 1 , wherein the contacting step is performed at a pH of from 7.5 to 9.0.

4. The method of claim 1 , wherein the contacting step is performed at a pH of from 7.5 to 8.5.

5. The method of claim 1 , wherein the contacting step is performed at a pH of from 7.3 to 8.0.

6. The method of claim 1 , wherein the contacting step is performed in a buffer having a pH that is −1 pH unit or higher than the calculated pI of the clostridial neurotoxin.

7. The method of claim 6 , wherein the buffer has a pH value that is equal to or higher than the calculated pI of said clostridial neurotoxin.

8. The method of claim 6 , wherein the buffer has a pH of between 0.2 and 1.5 pH units higher than the calculated pI of said clostridial neurotoxin.

9. The method of claim 6 , wherein the buffer has a pH of between 0.2 and 1.0 pH units higher than the calculated pI of said clostridial neurotoxin.

10. The method of claim 1 , further comprising contacting the composition comprising the single-chain clostridial neurotoxin with one or more additional resins.

11. The method of claim 1 , wherein at least 35% of the total clostridial neurotoxin comprised in the composition associates with the cation exchange resin.

12. The method of claim 1 , wherein the clostridial neurotoxin is a Clostridium botulinum neurotoxin, a Clostridium tetani neurotoxin, a Clostridium baratii neurotoxin, or a C. butyricum neurotoxin.

13. The method of claim 1 , wherein the clostridial neurotoxin is a botulinum neurotoxin (BoNT).

14. The method of claim 13 , wherein the BoNT is a cationic BoNT.

15. The method of claim 1 , wherein the protease is an endoprotease.

16. The method of claim 15 , wherein the endoprotease is Lys-C.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 5, 2018
From: HACKETT, GAVIN STEPHEN; PALAN, SHILPA
To: IPSEN BIOINNOVATION LIMITED
Reel/Frame 046786/0679 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 5, 2018
From: ANDERSON, DINA BRADY
To: IPSEN BIOPHARM LIMITED
Reel/Frame 046786/0729 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 5, 2018
From: IPSEN BIOINNOVATION LIMITED
To: IPSEN BIOPHARM LIMITED
Reel/Frame 046786/0810 →
Priority Claims (1)
GB 1517450 · Oct 2, 2015 · national
Continuity (1)
Related Publication 20190100564A1 · Apr 4, 2019